Global Gout Therapeutics Market Size Share Trends 2023-2030

Global Gout Therapeutics Market Overview:
The size of the gout therapeutics market was expected to be worth USD 1.9 billion in 2021 and is projected to increase at a compound annual growth rate (CAGR) of 8.2% to reach USD 4.1 billion by 2029 (2023-2030). A form of inflammatory arthritis known as gout arises when the body either produces too much uric acid or excretes too little of it. Gout may be chronic or acute. The tiny joints in the hands and feet are most commonly impacted by acute gout, which primarily affects the main extremity joints. Hard swellings called tophi (composed of uric acid) can develop on the joints in chronic gout and get so big that they even pierce the skin. The growing frequency of gout is one of the factors influencing the global market for gout therapies.

Download Sample: https://www.datamintelligence.com/download-sample/gout-therapeutics-market

Market Dynamics:
The market is expanding primarily due to the growing use of biologics, more research and development on regenerative medicine, and enhanced imaging modalities. Medications like colchicine, corticosteroids, nonsteroidal anti-inflammatory medications, and urate-lowering medicines can be used to treat or prevent this illness. Due to their superior outcomes, biologics are quickly taking the place of NSAIDs and corticosteroids in medical practice. Therefore, it is expected that the biologics category will rise quickly and that it will acquire gout treatments, which will fuel market expansion throughout the projection period. Growth in the market for gout disease treatments is anticipated to be driven by an increase in product approvals by regulatory bodies. To address the unmet needs of a sizable percentage of the patient population, manufacturers are implementing acquisition and collaboration strategies in addition to new product development tactics. Arhalofenate, a novel uricosuric drug under development, is thought to target the renal transporters of uric acid, particularly URAT1 and OAT4. Additionally, urate-lowering medications are used as a first line of treatment or in combination with other medications to treat the symptoms of gout arthritis.

Geographical Growth:
Due to the huge number of prominent competitors, the strong demand for gout therapy, and the high cost of branded pharmaceuticals in the United States, North America is now leading the global market for gout therapies, holding the greatest market share. Throughout the projection period, it is also anticipated that research and development of novel medications for the treatment of gout will dominate. Major pharmaceutical company Dr. Reddy's Laboratories introduced generic Colchicine to the US market in June 2020 with the goal of treating and preventing acute gout flare-ups.

Due to a diverse patient base, increasing major player investment in local manufacturers, and hospital chains in developing nations like China, India, South Korea, and other South Asian nations, the Asia Pacific region is predicted to grow at the fastest rate during the projection period. Gout cost the Australian health system an estimated USD 196.5 million in 2017-2018, accounting for 1.4% of illness expenditure on musculoskeletal disorders and 0.2% of total disease expenditure, according to the Australian Institute of Health and Welfare report 2022. Furthermore, it is anticipated that throughout this time, gout incidence would increase due to shifting lifestyles and an increase in the prevalence of alcohol and smoking.

The patient enrollment for the six-month, head-to-head, Phase 2 COMPARE clinical trial was completed in December 2022 by Selecta Biosciences, Inc., a clinical-stage biotechnology company dedicated to realizing the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR. The trial compares the effectiveness of pegloticase, the FDA-approved uricase medication currently used for adult patients with chronic refractory gout, administered twice a week to a once-monthly dosage of Selecta's lead product candidate, SEL-212 (ImmTOR + pegadricase).

Know More: https://www.datamintelligence.com/research-report/gout-therapeutics-market

Related Reports:

Rickets Treatment Market: https://www.datamintelligence.com/research-report/rickets-treatment-market

Temporomandibular Joint Implants Market: https://www.datamintelligence.com/research-report/temporomandibular-joint-implants-market

Kyphosis Treatment Market: https://www.datamintelligence.com/research-report/kyphosis-treatment-market

Sarcopenia Treatment Market: https://www.datamintelligence.com/research-report/sarcopenia-treatment-market

Psoriatic Arthritis Therapeutics Market: https://www.datamintelligence.com/research-report/psoriatic-arthritis-therapeutics-market

Musculoskeletal Diseases Treatment Market: https://www.datamintelligence.com/research-report/musculoskeletal-diseases-treatment-market

Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.